These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18351427)

  • 1. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.
    Sunyecz JA; Mucha L; Baser O; Barr CE; Amonkar MM
    Osteoporos Int; 2008 Oct; 19(10):1421-9. PubMed ID: 18351427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA; Amonkar MM; Hebborn A; Altman R
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
    Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG
    Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
    Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
    Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.
    Cramer JA; Lynch NO; Gaudin AF; Walker M; Cowell W
    Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and consequences of noncompliance to oral bisphosphonate treatment.
    Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
    J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
    Tosteson AN; Burge RT; Marshall DA; Lindsay R
    Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
    Rabenda V; Mertens R; Fabri V; Vanoverloop J; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
    Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J;
    Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
    Cramer JA; Gold DT; Silverman SL; Lewiecki EM
    Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
    Ganda K; Schaffer A; Pearson S; Seibel MJ
    Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.